Deals
Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Nektar is reportedly exploring various strategic options, including a possible sale, partnerships or licensing agreements.
NCPC GeneTech, the biotech division of North China Pharma, in-licensed China rights for a biosimilar to a second-gen renal anemia treatment from South Korea’s CJ Healthcare.
The company plans to raise $30 million by offering 4.3 million shares at a price range of $6 to $8.
Amgen reported its fourth-quarter financials yesterday, but in anticipation of this year’s hot merger-and-acquisition market, a lot of focus has been on the company’s considerable available cash.
Only a week after launch, Partner Therapeutics acquired the global rights to Leukine from Sanofi.
The company expects to only pay a tax rate of 9 percent this year, which will free up a lot of cash.
Seattle Genetics is paying $10 per share in cash for Cascadian.
With 2018 expected to be a big year for mergers and acquisitions in the biopharma industry, analysts and investors are considering who the top targets might be.
A look at three small biotechs that big drugmakers are drooling over.
Only a week after Sanofi ponied up $11.6B to buy Waltham, Massachusetts-based Bioverativ, the French drugmaker is buying Ghent, Belgium-based Ablynx for $4.8B.